Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1014results about "Eye implants" patented technology

Long wearable soft contact lens

The present invention relates to a soft contact lens, and provides a contact lens which shows small and stable contact angle to water at its surface in water as well as in air, little deposition in wearing, high oxygen permeability, no adhesion of lens to a cornea and superior extended-wearing characteristics. The present invention provides a hydrogel soft contact lens which has contact angle at a lens surface in a range of 10-50° by the captive bubble method in water and 30-90° by the sessile drop method in air, oxygen permeability of not less than 30 and water content of not less than 5%, and also a hydrogel soft contact lens consisting of a polymer comprising a hydrophilic siloxanyl monomer shown by a specified general formula.
Owner:COOPERVISION INT LTD

Biocompatible implant and use of the same

InactiveUS20060252981A1Good biological affinityStrong enoughImpression capsEye implantsRough surfaceBiological body
The present invention provides an implant capable of being cellularized in treatment of an injured organ or tissue in organisms. The present inventors found that a biocompatible implant comprising a biological molecule and a support is capable of being cellularized. The implant can be used instead of conventional implants which essentially comprise cells. The present invention provides a biocompatible implant comprising A) a biological molecule and B) a support. The present invention also provides A) a first layer having a rough surface, B) a rough surface; B) a second layer having a strength which allows the support to resist in vivo shock. The first layer is attached to the second layer via at least one point.
Owner:CARDIO

Expandable glaucoma implant and methods of use

Disclosed is an implant for use in an eye with glaucoma, the implant including an inlet section in fluid communication with an outlet section, the inlet section being sized and shaped to fit at least partially in the anterior chamber of the eye, and the outlet section being sized and shaped to fit at least partially in Schlemm's canal of the eye. The implant also includes an expandable substrate suitable for expansion in the eye to assist in retaining the implant in the eye.
Owner:GLAUKOS CORP

Device for improving in a targeted manner and/or permanently ensuring the ability of the aqueous humor to pass through the trabecular meshwork

A device is disclosed for selectively improving and / or permanently ensuring the permeability for ocular aqueous humour through the trabecular formations into Schlemm's canal. A small tubular element is provided, whose wall material encloses a hollow duct that presents an open configuration on both ends along the longitudinal extension of the hollow duct, so that the size and the shape of the small tubular element correspond approximately to the internal contour of Schlemm's canal, and the wall material as well as the wall thickness are so selected that upon introduction into Schlemm's canal the small tubular element keeps the canal open and dilates adjacent trabecular formations.
Owner:NEUHANN THOMAS

Ocular pressure regulation

This invention comprises a flexible ocular device for implantation into the eye formed of a biocompatible elastomeric material, foldable to a diameter of 1.5 mm or less, comprising a fluid drainage tube having at one end a foldable plate adapted to locate the device on the inner surface of the sclera in a suprachoroidal space formed by cyclodialysis, said drainage tube opening onto the disc at one end and opening to the anterior chamber when implanted into the eye at its other end, so as to provide aqueous pressure regulation. Also provided are methods for the treatment of glaucoma utilising the flexible ocular device, and an ocular pressure spike shunt.
Owner:ALCON INC

Surgical correction of human eye refractive errors by active composite artificial muscle implants

Surgical correction of human eye refractive errors such as presbyopia, hyperopia, myopia, and stigmatism by using transcutaneously inductively energized artificial muscle implants to either actively change the axial length and the anterior curvatures of the eye globe. This brings the retina / macula region to coincide with the focal point. The implants use transcutaneously inductively energized scleral constrictor bands equipped with composite artificial muscle structures. The implants can induce enough accommodation of a few diopters, to correct presbyopia, hyperopia, and myopia on demand. In the preferred embodiment, the implant comprises an active sphinctering smart band to encircle the sclera, preferably implanted under the conjunctiva and under the extraocular muscles to uniformly constrict the eye globe, similar to a scleral buckle band for surgical correction of retinal detachment, to induce active temporary myopia (hyperopia) by increasing (decreasing) the active length of the globe. In another embodiment, multiple and specially designed constrictor bands can be used to enable surgeons to correct stigmatism. The composite artificial muscles are either resilient composite shaped memory alloy-silicone rubber implants in the form of endless active scleral bands, electroactive ionic polymeric artificial muscle structures, electrochemically contractile endless bands of ionic polymers such as polyacrylonitrile (PAN), thermally contractile liquid crystal elastomer artificial muscle structures, magnetically deployable structures or solenoids or other deployable structures equipped with smart materials such as preferably piezocerams, piezopolymers, electroactive and eletrostrictive polymers, magnetostrictive materials, and electro or magnetorheological materials.
Owner:ENVIRONMENTAL ROBOTS

Scleral prosthesis for treatment of presbyopia and other eye disorders

InactiveUS6280468B1Increase the effective working distanceIncrease the working distanceLaser surgeryEye implantsDiseaseOpen angle glaucoma
Presbyopia is treated by implanting within a plurality of elongated pockets formed in the tissue of the sclera of the eye transverse to a meridian of the eye, a prosthesis having an elongated body having a first surface and a second surface opposite the first surface to contact the base and flap of the scleral pocket. The first and second surfaces are spaced apart a distance so that the implanted prosthesis exerts an outward force on the flap of the scleral pocket which results in an outward traction on at least the anterior margin of the scleral pocket. The combined effect of the implanted prostheses is to exert a radially outward traction on the sclera in the region overlying the ciliary body which expands the sclera in the affected region together with the underlying ciliary body. The expansion of the ciliary body restores the effective working distance of the ciliary muscle in the presbyopic eye and thereby increases the amplitude of accommodation. Hyperopia, primary open angle glaucoma and / or ocular hypertension can be treated by increasing the effective working distance of the ciliary muscle according to the invention. A preferred embodiment of the scleral prosthesis has a major surface adapted to contact the base or flap of the pocket and an opposite surface or ridge spaced from the major surface.
Owner:REFOCUS GROUP

Posterior Segment Drug Delivery

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. Each of the openings on the first side can be connected to each of the openings on the second side with the plurality of interconnecting channels, such that the rate of release of the therapeutic agent can be substantially maintained when one or more of the openings is blocked, for example with particles, cells, bacteria or tissue when the device is implanted for an extended time. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device many comprise an expandable retention structure and an expandable reservoir, such that the device can be delivered from a lumen of a delivery device and expand when positioned in the patient. The therapeutic device may comprises a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.
Owner:FORSIGHT VISION5 INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products